Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

 

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Sevelamer hydrochloride Manufacturers in India Suppliers Sevelamer hydrochloride Exporters Distributors Sevelamer hydrochloride api active pharmaceuticals ingredients Sevelamer hydrochloride manufacturers Side Effects bulk drugs raw material Sevelamer hydrochloride companies Side Effects Importers Sevelamer hydrochloride Sevelamer hydrochloride Exporters Sevelamer hydrochloride exporters FDA Sevelamer hydrochloride DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Sevelamer hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Sevelamer hydrochloride pharmaceutical chemicals pharmaceutical raw materials Sevelamer hydrochloride active pharmaceutical ingredients Sevelamer hydrochloride committee active pharmaceutical ingredients manufacturer Sevelamer hydrochloride Active Pharmaceutical Ingredients manufacturer Sevelamer hydrochloride exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Sevelamer hydrochloride, Sevelamer hydrochloride manufacturer India, Sevelamer hydrochloride product, Sevelamer hydrochloride products, Api preparation, Certificate of Analysis API manufacturer product, Sevelamer hydrochloride anti ulcer product, Certificate of Origin COA Sevelamer hydrochloride COS Sevelamer hydrochloride, pharmaceutical generic, pharmaceutical drug, medical, Sevelamer hydrochloride pharma healthcare, pharma patents, contract MSDS manufacturing Trader Sevelamer hydrochloride pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Sevelamer hydrochloride expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Sevelamer hydrochloride DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Sevelamer hydrochloride ingredients, api, HIV Sevelamer hydrochloride, tablets, capsules, syrup & protein Sevelamer hydrochloride powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Sevelamer hydrochloride gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Sevelamer hydrochloride WHO, UKMHRA Approval

 
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
   

Sevelamer hydrochloride Sevelamer hydrochloride


Sevelamer hydrochloride Sevelamer hydrochloride


Sevelamer hydrochloride Sevelamer hydrochloride



 

 

 

 

 

 

 

 

 

 











 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HOME >> API >> API List 3 >> Sevelamer Hydrochloride




Name: Sevelamer hydrochloride
pdf api

Sevelamer Hydrochloride

CAS Number : 152751-57-0

Synonyms: 2-(chloromethyl)oxirane; prop-2-en-1-amine; hydrochloride; 2-Propen-1-amine,hydrochloride,polymer with (chloromethyl)oxirane; RenaGel (TN); Sevelamer hydrochloride (JAN/USAN);Sevelamer HCL; RenaGel;

Molecular Formula: (C3H7N)m. (C3H5ClO)n.(HCl)x


Assay: 99% min
An Improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g comprising the steps of: (a) dissolving polyallylamine hydrochloride in water to obtain an aqueous solution; (b) partially neutralizing the aqueous solution of polyallylamine hydrochloride with 65 to 70 mole % of alkali with respect to polyallylamine hydrochloride; (c) charging dispersing agent to hydrocarbon solvent to obtain solution; (d) mixing partially neutralized aqueous polyallylamine hydrochloride solution with the solution obtained in step (c); (e) stirring the obtained reaction mixture at speed of about 40 to about 250 revolutions per minute to get fine dispersion of aqueous phase in organic phase; (f) heating the suspension obtained in step (e) at elevated temperature; (g) charging 5 to 12 % by weight of epichlorohydrin with respect to polyallylamine hydrochloride to the suspension of step (f) maintaining elevated temperature till cross linking is complete; (h) cooling the reaction mixture at temperature of 25 to 35 C. and isolating the compound by washing the obtained cake with water and (i) drying the wet cake in a Fluidized Bed Dryer at temperature of about 25 C. to about 90 C. to get Sevelamer hydrochloride with phosphate binding capacity of 4.7 to 6.4 mmol/g.

Detailed offer Description

Sevelamer Hydrochloride is a polymeric amine that binds phosphate and is meant for oral administration. Sevelamer hydrochloride is poly(allylamine hydrochloride) crosslinked with epichlorohydrin in which forty percent of the amines are protonated. It is known chemically as poly (allylamine-co-N,N'-diallyl- 1,3-diamino-2-hydroxypropane) hydrochloride. Sevelamer hydrochloride is hydrophilic, but insoluble in water.

Object Of The Invention

The main object of the present invention is to provide industrial process for preparation of Sevelamer hydrochloride having PA in the range of about 4.7 mmol/g to about 6.4 mmol/g and chloride content in the range of about 3.74 to about 5.60 meq/g.

Another object of the invention is to provide pharmaceutical compositions comprising a therapeutically effective amount of Sevelamer hydrochloride along with suitable pharmaceutically acceptable excipients.

Another object of the invention is to provide a novel process for preparation of Sevelamer hydrochloride compositions comprising high shear non-aqueous granulation.

Another object of the invention is to provide improved and simplified process for preparation of Sevelamer hydrochloride which will eliminate the use of acetonitrile and the risk of gelling also avoid use of IPA for removing water.

Another object of the invention is to provide Sevelamer hydrochloride which will meet the stringent ICH (International Committee of Harmonisation) requirements.

Yet another object of the invention is to provide process which yields Sevelamer hydrochloride having consistency in degree of cross linking and avoids the need of specialized equipments for the manufacture of the said product and thereby reducing the manufacturing cost.

Still another object of the invention is to provide compositions for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.

Another object of the invention is to provide method for reducing the serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis comprising administering a therapeutically effective amount of Sevelamer hydrochloride along with suitable pharmaceutically acceptable excipients.

Detailed Description Of The Invention

The present invention describes an industrial process for the preparation of Sevelamer hydrochloride. The present invention further involves improved process for crosslinking polyallylamine hydrochloride dispersed in an organic medium with epichlorohydrin to obtain Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g.

The present invention further describes pharmaceutical compositions comprising a therapeutically effective amount of Sevelamer hydrochloride along with suitable pharmaceutically acceptable excipients. A novel process for preparation of said Sevelamer hydrochloride compositions comprising high shear non-aqueous granulation is also described.

According to one embodiment of the invention process for preparation of Sevelamer hydrochloride according to the invention comprises the steps of;


(a) dissolving polyallylamine hydrochloride in water to obtain an aqueous solution;
(b) partially neutralizing the aqueous solution of polyallylamine hydrochloride with 65 to 70 mole % of alkali with respect to polyallylamine hydrochloride;
(c) charging dispersing agent to hydrocarbon solvent to obtain solution;
(d) mixing partially neutralized aqueous polyallylamine hydrochloride solution with the solution obtained in step (c);
(e) stirring the obtained reaction mixture at speed of about 40 to about 250 revolutions per minute to get fine dispersion of aqueous phase in organic phase;
(f) heating the suspension obtained in step (e) at an elevated temperature;
(g) charging 5 to 12% by weight of epichlorohydrin with respect to polyallylamine hydrochloride to the suspension of step (f) maintaining an elevated temperature till cross linking is complete;
(h) cooling the reaction mixture at temperature of 25 to 35 C. and isolating the compound by washing the obtained cake with water and filtration;
(i) drying the wet cake in a Fluidized Bed Dryer at temperature of about 25 to 90 C. to get Sevelamer hydrochloride with phosphate binding capacity of 4.7 to 6.4 mmol/gm.

Sevelamer hydrochloride prepared by the process described by the present invention is used in formulating Sevelamer hydrochloride compositions.

Phosphate binding polymer Sevelamer is water insoluble but it swells in contact with water. Due to this tendency of swelling, formulating Sevelamer by aqueous granulation becomes difficult. Although attempts have been made to formulate Sevelamer by wet granulation method, none of the prior art discloses a successful process for high shear non-aqueous granulation being carried out in an equipment such as a high shear rapid mixer granulator or a planetary mixer.

Inventors of the present invention attempted granulation of Sevelamer hydrochloride using spray granulation technique. However, the results were not satisfactory since the binding solution containing ethylcellulose dissolved in isopropyl alcohol was very viscous and posed problem for uniform spraying of the granulating fluid on to the active ingredient and also the dry mass becomes tacky and forms sticky lumps.

Attempts were also made for preparation of Sevelamer hydrochloride compositions by hot melt granulation and hot melt extrusion techniques but the results were not satisfactory as very high quantity of binder was required and granules produced were lacking adequate flow properties.

Although the prior art states that tableting of a phosphate binding polymer such as Sevelamer hydrochloride is impossible by wet granulation, the inventors of the present invention have successfully developed a novel process for granulation of Sevelamer hydrochloride by high shear non-aqueous granulation.

According to the present invention, the process for preparation of Sevelamer hydrochloride compositions comprising high shear non-aqueous granulation comprises the steps of:


(a) preparing a mixture of Sevelamer hydrochloride and one or more diluents;
(b) optionally wetting the prepared mixture;
(c) preparing a non-aqueous binder solution by dissolving binder in an organic solvent;
(d) granulating the mixture of step (a) or step (b) with non-aqueous binder solution by high shear non-aqueous granulation to form granulated mass;
(e) drying the granulated mass;
(f) milling the dried mass using ball mill or fluid energy mill to form granules of suitable size;
(g) lubricating the milled granules;
(h) compressing the lubricated granules into tablets or filling the lubricated granules into capsules;
(i) coating the compressed tablets.

According to the invention, the particles of Sevelamer hydrochloride are round in shape, particularly spherical or oval in shape. Spherical or oval shaped particles of Sevelamer hydrochloride have low bulk density and poor flowability and further resist size reduction. Particles resist deformation and do not rupture or fracture. Due to these characteristics of Sevelamer hydrochloride, formulating Sevelamer hydrochloride by direct compression method becomes extremely difficult. In the practice of the present invention, although the spherical morphology and hydrophilic nature of active ingredient Sevelamer hydrochloride presents a special challenge to the formulator, the inventors of the present invention have successfully prepared Sevelamer hydrochloride compositions by high shear non-aqueous granulation and by using rapid mixer granulator or planetary mixer.

Sevelamer hydrochloride is not a free flowing powder and is bulky. Wetting with purified water helps in decreasing the interparticulate distance and increasing the contact area between the particles; thus making Sevelamer Hydrochloride more amenable for the non-aqueous granulation. Wetting is carried out either in a rapid mixer granulator or a planetary mixer. In the practice of the present invention, wetting of mixture of active and diluent is carried out using about 2% to 9% by weight of purified water. Alternatively, the mixture of active and diluent may be made wet using a solution of polyethylene glycol dissolved in purified water. In an alternate method, polyethylene glycol 6000 may be added into the dry mix as a fine powder during the mixing step. Polyethylene glycols of various grades may be used such as polyethylene glycol 6000 or the like.




                                
Detail icon
PDF DOWNLOAD      WORD DOCUMENT        Details

Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

 

 

Taj pharmaceuticals API Logo

 

Sevelamer hydrochloride

More Api at Taj Pharmaceuticals Ltd.

Alfuzosin

Oseltamivir Phosphate

 Amlodipine Besylate

Aripiprazole

Atorvastatin Calcium

Candesartan Cilaxetil

Cefdinir

Cetirizine Dihydrochloride

Ciprofloxacin HCl

Dextromethorphan Base

Diltiazem HCl

Domperidone Base

Domperidone Maleate

Doxazosin Mesylate

 Duloxetine HCl

Dutasteride

Enalapril Maleate

Esomeprazole Magnesium

Famotidine

Fexofenadine HCl

Fluconazole

Fluoxetine HCl

Galantamine HBr

Ibuprofen

Caffeine

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.